3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
2
Withdrawn
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
2
Thoracic
2
Head & Neck
2
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Endocrine
2
Breast
2
Sarcoma
1
Other solid neoplasm
1
NET
1
Dermatologic
1
CNS
1
Conditions
Neuroendocrine Tumors
19
Carcinoid Tumor
5
Pheochromocytoma
4
Paraganglioma
3
Gastro-enteropancreatic neuroendocrine tumor
3
Vipoma
2
Neoplasms
2
Insulinoma
2
Carcinoma, Merkel Cell
2
Zollinger-Ellison Syndrome
1
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Serotonin Syndrome
1
Pancreatic Neoplasms
1
Non functioning pancreatic endocrine tumor
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Neoplasms, Cystic, Mucinous, and Serous
1
Multiple Endocrine Neoplasia Type 2b
1
Multiple Endocrine Neoplasia Type 2a
1
Multiple Endocrine Neoplasia Type 1
1
Lung Neoplasms
1
Liver Neoplasms
1
Hypoglycemia
1
Glucagonoma
1
Gastrinoma
1
Diarrhea
1
Carcinoma, Medullary
1
Cachexia
1
Adrenal Gland Neoplasms
1
Interventions
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Neoplasms, Unknown Primary
×
NET
×
Clear all
NCT04276597
2023-03-10
PUTNET
Excel Diagnostics and Nuclear Oncology Center
Phase 2
Withdrawn